Research Funding

DOD Peer Reviewed Alzheimer’s Research Program

The following is a summary of the FY18 PRARP Program Announcements.  Four award mechanisms will be offered for FY18.

http://cdmrp.army.mil/funding/prarp

Convergence Science Research Award – Letter of Intent due September 20, 2018

Principal Investigators (PIs) at or above the level of Assistant Professor (or equivalent).

Intent:  Support efforts to generate research resources, tools, or novel research efforts for researchers and/or practitioners in health sciences.

Applications must address one or more of the following FY18 PRARP Overarching Challenges:

  • Paucity of Research Resources
  • Paucity of Clinical Studies
  • Diagnostic Technologies, Tests, Biomarkers, or Devices
  • Epidemiology

Applications should address at least one of the following FY18 PRARP Focus Areas:

  • Mechanisms of Pathogenesis
  • Biomarkers
  • Epidemiological Research
  • Novel Target Identification

Research considering pharmacologic interventions is specifically discouraged under this mechanism.

Preliminary data, while not required, are encouraged.

  • Maximum funding is $500,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 3
  • Indirect costs may be proposed in accordance with the institution’s rate agreement.

Quality of Life Research Award (QUAL) – Letter of Intent due September 20, 2018

PIs at or above the level of Assistant Professor (or equivalent).

Intent:  The intent of the QUAL mechanism is to support preclinical, basic, epidemiological, or quality-of-life research to alleviate or characterize the common symptoms of TBI and AD/ADRD.

Applications must address one or more of the following FY18 PRARP Overarching Challenges:

  • Paucity of Clinical Studies
  • Epidemiology
  • Quality of Life
  • Caregiver Support

Applications should address at least one of the following FY18 PRARP Focus Areas:

  • Biomarkers
  • Quality of Life
  • Caregiver Support
  • Nonpharmacological Interventions
  • Epidemiological Research

Research considering pharmacologic interventions is specifically discouraged under this mechanism.

Preliminary data, while not required, are encouraged.

  • Funding limit is $500,000 in direct costs.
  • Maximum period of performance is 3 years.
  • Indirect costs may be proposed in accordance with the institution’s rate agreement.

New Investigator Award – Letter of Intent due September 20, 2018

The PI must be an independent, early-career investigator within 3 years of his/her first independent faculty position (or equivalent).

Intent:  Support early-career investigators interested in novel research efforts or new technologies within TBI and AD/ADRD.

Applications must address one or more of the following FY18 PRARP Overarching Challenges:

  • Paucity of Research Resources
  • Paucity of Clinical Studies
  • Diagnostic Technologies, Tests, Biomarkers, or Devices
  • Epidemiology
  • Quality of Life
  • Caregiver Support

Applications should address at least one of the following FY18 PRARP Focus Areas:

  • Mechanisms of Pathogenesis
  • Biomarkers
  • Quality of Life
  • Caregiver Support
  • Epidemiological Research
  • Novel Target Identification
  • Nonpharmacological Interventions

Research considering pharmacologic interventions is specifically discouraged under this mechanism.

Preliminary data, while not required, are encouraged.

  • Funding limit is $225,000 in direct costs.
  • Maximum period of performance is 3
  • Indirect costs may be proposed in accordance with the institution’s rate agreement.

Research Partnership Award – Letter of Intent due September 20, 2018

The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

Intent:  To create an avenue for partnerships between investigators to address a research problem or question in a manner that would be unachievable through separate efforts.

Applications must include clearly stated plans for interactions between the partners. The plans must include communication, coordination of research progress and results, and data sharing between all investigators and organizations participating in the project.

Applications must address one or more of the following FY18 PRARP Overarching Challenges:

  • Paucity of Research Resources
  • Paucity of Clinical Studies
  • Diagnostic Technologies, Tests, Biomarkers, or Devices
  • Epidemiology
  • Quality of Life
  • Caregiver Support

Applications should address at least one of the following FY18 PRARP Focus Areas:

  • Mechanisms of Pathogenesis
  • Biomarkers
  • Quality of Life
  • Caregiver Support
  • Epidemiological Research
  • Novel Target Identification
  • Nonpharmacological Interventions

Research considering pharmacologic interventions is specifically discouraged under this mechanism.

Preliminary data are required.

  • Funding limit is $1.3M in total costs.
  • Maximum period of performance is 3
  • Indirect costs may be proposed in accordance with the institution’s rate agreement.

 A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that are available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRARP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
heklp@eBrap.org

Leave a Reply

Time limit is exhausted. Please reload CAPTCHA.